THE ROLE OF NEW BIOMARKERS IN ACUTE KIDNEY INJURY DETECTING IN CRITICAL CONDITION PATIENTS

V. Sharipova, N. Berdiev, O. Lutfullaev, A. Mikhliev

Abstract

https://doi.org/10.54185/TBEM/vol14_iss3/a10

Acute kidney injury is a polyetiologic syndrome that is a sudden decrease in kidney function over several
days or weeks, causing the accumulation of nitrogenous compounds in the blood, with or without a decrease
in urine output. Acute kidney injury is common in hospitalized patients and is associated with increased
morbidity, mortality, and financial costs. Currently, acute kidney injury is diagnosed after the onset of
symptoms; Available diagnostic tests (presence of creatinine in the blood, microscopy of urine, urine
volume) have shortcomings in identifying subclinical acute kidney injury. The lack of therapeutic strategies
leads to the fact that the treatment of acute kidney injury is carried out with the help of supportive therapies.
Early acute kidney injury detection is essential to minimize damage. Experimental and clinical studies have
identified a new biomarker that contribute to the earlier diagnosis of acute kidney injury. With their help,
it can be determined that patients are at risk of acute kidney damage. In this review, the authors describe
some of the most promising new AKI biomarkers (neutrophil gelatinase-associated lipocalin (NGAL), kidney
injury molecule (KIM-1), interleukin-18 (IL18), tissue inhibitor of metalloproteinase-2 (TIMP-2), protein -7,
which binds insulin-like growth factor (IGFBP7)).